Schenck LP, Beck PL, MacDonald JA. Gastrointestinal dysbiosis and the use of fecal microbial transplantation in Clostridium difficile infection. World J Gastrointest Pathophysiol 2015; 6(4): 169-180 [PMID: 26600975 DOI: 10.4291/wjgp.v6.i4.169]
Corresponding Author of This Article
Justin A MacDonald, Professor, Gastrointestinal Research Group at the Snyder Institute for Chronic Diseases and Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary AB T2N 4Z6, Canada. jmacdo@ucalgary.ca
Research Domain of This Article
Methodology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Pathophysiol. Nov 15, 2015; 6(4): 169-180 Published online Nov 15, 2015. doi: 10.4291/wjgp.v6.i4.169
Gastrointestinal dysbiosis and the use of fecal microbial transplantation in Clostridium difficile infection
L Patrick Schenck, Paul L Beck, Justin A MacDonald
L Patrick Schenck, Gastrointestinal Research Group at the Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary AB T2N 4Z6, Canada
Paul L Beck, Gastrointestinal Research Group at the Snyder Institute for Chronic Diseases and Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary AB T2N 4Z6, Canada
Justin A MacDonald, Gastrointestinal Research Group at the Snyder Institute for Chronic Diseases and Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB, T2N 4Z6, Canada
Author contributions: Schenck LP, Beck PL and MacDonald JA performed the literature review and wrote the paper.
Supported by Canadian Institutes of Health Research, No. MOP#98004.
Conflict-of-interest statement: The authors declare that they have no affiliation with or involvement in any organization or entity with any financial interest in the subject matter or materials discussed in this manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Justin A MacDonald, Professor, Gastrointestinal Research Group at the Snyder Institute for Chronic Diseases and Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary AB T2N 4Z6, Canada. jmacdo@ucalgary.ca
Telephone: +1-403-2108433
Received: June 25, 2015 Peer-review started: June 26, 2015 First decision: August 16, 2015 Revised: August 28, 2015 Accepted: October 12, 2015 Article in press: October 13, 2015 Published online: November 15, 2015
Core Tip
Core tip: Emergent literature demonstrates the critical role of the human microbiota in the susceptibility to Clostridium difficile (C. difficile) infection (CDI). Microbial communities may exert effects on the metabolic composition within the GI tract that influence CDI pathogenesis (e.g., bile salt metabolism). The identification of protective and susceptible human gut microbiomes would enable the development of screening tools to identify at-risk patients. Ultimately, the rational design of probiotic cocktails could assist in attenuating C. difficile transmission in hospital or community settings. Prevention of CDI would lead to decreased morbidity and mortality, as well as reduction of hospitalization time and health care costs associated with treatment.
